ZYVERSA THERAPEUTICS, INC. Payments of Debt Issuance Costs
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Payments of Debt Issuance Costs of $366.62 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-09-30 was $219.49K.
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-06-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-03-31 was $147.13K.
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2025 was $366.62K, a 37.65% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2024 was $588.04K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $219.49K derived: sum of 2 quarters · filed 2026-03-31 | $219.49K derived: sum of 3 quarters · filed 2026-03-31 | $366.62K 10-K · filed 2026-03-31 |
| 2025-09-30 | $219.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $219.49K derived: sum of 2 quarters · filed 2025-11-19 | $366.62K 10-Q · filed 2025-11-19 | $774.52K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $147.13K 10-Q · filed 2025-08-13 | $555.03K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2025-03-31 | $147.13K 10-Q · filed 2026-05-13 | $555.03K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $407.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $588.04K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $180.14K 10-Q · filed 2025-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |